THE IMMUNOLOGY OF CANINE LEISHMANIASIS - STRONG EVIDENCE FOR A DEVELOPING DISEASE SPECTRUM FROM ASYMPTOMATIC DOGS

Citation
M. Cabral et al., THE IMMUNOLOGY OF CANINE LEISHMANIASIS - STRONG EVIDENCE FOR A DEVELOPING DISEASE SPECTRUM FROM ASYMPTOMATIC DOGS, Veterinary parasitology, 76(3), 1998, pp. 173-180
Citations number
21
Categorie Soggetti
Parasitiology,"Veterinary Sciences
Journal title
ISSN journal
03044017
Volume
76
Issue
3
Year of publication
1998
Pages
173 - 180
Database
ISI
SICI code
0304-4017(1998)76:3<173:TIOCL->2.0.ZU;2-4
Abstract
Asymptomatic mixed breed dogs (49) from a region of high incidence of visceral leishmaniosis in Portugal were examined for the presence of L eishmania-specific cellular immunity using a proliferation assay and h umoral immunity using an indirect antibody fluorescent test (IFAT) and an ELISA. The results were compared directly with 25 mixed breed dogs permanently residing in a non-endemic region (Scotland). Unlike simil ar studies in humans from non-endemic areas, there was no evidence of any immunological response against leishmanial antigen whatsoever from the latter group of animals. Of the 49 dogs from Portugal, however, 2 0 had demonstrable parasite specific cellular immunity. Depending on t he assay and criteria used to measure a positive humoral response, 11, 16 or 24 dogs had a Leishmania-specific humoral response with the ELI SA being the most sensitive assay system. While 16, 12 or 8 of the dog s had clearly only a cellular response (depending on which criterion w as used to constitute a true antibody response) and 7, 8 or 12 had onl y humoral response, other 4, 8 or 12 of the dogs had both cellular and humoral responses. This study clearly demonstrates that the infection rate of canine leishmaniosis is not only higher than previously thoug ht using serological tests alone but that the response to infection is already highly polarised in many asymptomatic does. It is postulated that an individual dog's position within the immunological spectrum is likely to indicate how the disease will progress. (C) 1998 Elsevier S cience B.V.